In Vitro and In Vivo Activities of the Novel Azole Antifungal Agent R126638
AUTOR(ES)
Odds, F.
FONTE
American Society for Microbiology
RESUMO
R126638 is a new triazole agent with potent antifungal activity in vitro against various dermatophytes, Candida spp., and Malassezia spp. Its activity against Malassezia spp. in vitro was superior to that of ketoconazole, the agent currently used for the treatment of Malassezia-related infections. R126638 showed activity comparable to or lower than that of itraconazole against dermatophytes in vitro; however, in guinea pig models of dermatophyte infections, R126638 given orally consistently showed antifungal activity superior to that of itraconazole, with 50% effective doses (ED50s) three- to more than eightfold lower than those of itraconazole, depending on the time of initiation and the duration of treatment. The ED50 of R126638 in a mouse dermatophytosis model was more than fivefold lower than that of itraconazole. These data indicate that if the effects of R126638 seen when it is used to treat animals can be extrapolated to humans, the novel compound would be expected to show effects at doses lower than those of existing drugs and, hence, present a lower risk for side effects.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=321549Documentos Relacionados
- The Novel Azole R126638 Is a Selective Inhibitor of Ergosterol Synthesis in Candida albicans, Trichophyton spp., and Microsporum canis
- In Vitro and In Vivo Activities of CS-758 (R-120758), a New Triazole Antifungal Agent
- In vitro and in vivo antifungal activities of D0870, a new triazole agent.
- In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304.
- In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.